UnitedHealthCare (Minnetonka, MN), one of the nation’s largest private payors, will now reimburse for Oncotype DX, Genomic Health’s breast cancer test service. United’s new policy establishes coverage across all of UnitedHealthcare’s plans for women with early-stage breast cancer. Coverage is scheduled to become effective for claims for services performed after January 2 of this year. Oncotype DX quantifies the likelihood of breast cancer recurrence and predicts the likelihood of chemotherapy benefit for some early-stage breast cancer patients.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

February 2007 - Table of Contents

LIR February 2007 (full PDF issue)

Lab Industry Follows Pharma Into Direct-to-Consumer Marketing

Lab Execs Map Out Competitive Strategies

Sonic Deviates From Offshore Strategy, Acquires Remaining 18% of CPL

Horizon/LabCorp Deal Ousts Bio-Reference

RedPath Builds on a Convergence of Technology

New Congress to Influence Critical Laboratory, Pathology Issues

Cutting Out the Middle Man? Major Lab Players Target Patients in New Media Campaigns

Spectrum to Use Thomson’s MercuryMD Mobile EHR System

United Will Cover Oncotype DX Testing

Lab Stocks Rose 29% In 2006; Genomic Health Was Best Performer

FDA to Hold Meeting on IVDMIAs